The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia

Sleep

Volumn 35, Issue 8, 2012, Pages 1097-1104

  Bettica, Paolo ^a   Squassante, Lisa ^a   Zamuner, Stefano ^b   Nucci, Gianluca ^b   Danker Hopfe, Heidi ^c   Ratti, Emiliangelo ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Hypocretin; Insomnia; Orexin; Polysomnography; SB 649868

Indexed keywords

PLACEBO; SB 649868;

ADULT; ALERTNESS; ARTICLE; ATTENTION; COGNITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; GERMANY; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR CONTROL; MULTICENTER STUDY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; RHINOPHARYNGITIS; SELF REPORT; SLEEP INDUCTION; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; VITAL SIGN; XEROSTOMIA;

HYPOCRETIN; INSOMNIA; OREXIN; POLYSOMNOGRAPHY; SB-649868;

ADOLESCENT; ADULT; BENZOFURANS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; GERMANY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMORY; MIDDLE AGED; NEUROPEPTIDES; PLACEBOS; POLYSOMNOGRAPHY; QUESTIONNAIRES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP, REM; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84864766771     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.1996     Document Type: Article

References (30)

1. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry 2011;69:592-600.
2. Winsky-Sommerer R. Role of GABAA receptors in the physiology and pharmacology of sleep. Eur J Neurosci 2009;29:1779-94.
3. Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18.
4. Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009;61:162-76.
5. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 1999;96:10911-6. (Pubitemid 29442243)
6. Piper DC, Upton N, Smith MI, et al. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000;12:726-30. (Pubitemid 30142774)
7. Brown RE, Sergeeva O, Eriksson KS, et al. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology 2001;40:457-9. (Pubitemid 32144724)
8. Eriksson KS, Sergeeva O, Brown RE, et al. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001;21:9273-9. (Pubitemid 33096871)
9. Saper CB, Fuller PM, Pedersen NP, et al. Sleep state switching. Neuron 2010;68:1023-42
10. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 20;98:437-51. (Pubitemid 29402482)
11. Chen W, Zeitzer JM, Mignot E. The hypocretins and narcolepsy. In: Lecea L, Sutcliffe JG, eds. Hypocretins: integrators of physiological functions. New York: Springer, 2005:233-52.
12. Gerrard PA, Porter RA, Holland V, et al. Preclinical pharmacology of SB-649868: a novel orexin OX1/OX2 receptor antagonist possessing potent hypnotic activity in rodents and primates. Sleep 2009;32:A42.
13. Bettica P, Nucci G, Pyke C, et al. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868 - A novel dual orexin receptor antagonist. J Psychopharmacology 2011, July 5 (Epub ahead of print).
14. Rechtschaffen A, Kales A, eds. A manual for standardized terminology, techniques and scoring system for sleep stages on human subjects. Washington DC: National Institute of Health, Publication 204, 1968.
15. Renzulli C, Nash M, Wright M, et al. Disposition and metabolism of [14C]SB-649868 an orexin 1 and 2 receptor antagonist in humans. Drug Metab Dispos 2011;39:215-27
16. Beal SL, Sheiner LB. NONMEM user's guides. San Francisco: NONMEM Project Group, 1998.
17. Wechsler D. Wechsler Adult Intelligence Scale-Revised. Manual. New York: Psychological Corporation, 1981.
18. Jansen AA, de Gier JJ, Slangen JL. Diazepam-induced changes in signal detection performance. A comparison with the effects on the Critical Flicker-Fusion Frequency and the Digit Symbol Substitution Test. Neuropsychobiology 1986;16:193-7. (Pubitemid 17084408)
19. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999;48:367-74. (Pubitemid 29417720)
20. Helmstaedter C, Durwen HF. The Verbal Learning and Retention Test. A useful and differentiated tool in evaluating verbal memory performance. Schweiz Arch Neurol Psychiatr1990;141:21-30. (Pubitemid 20112622)
21. Rey A. L'examen psychologique dans les cas d'encéphalopathie traumatique. Paris: Presses Universitaires de France, 1964.
22. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50. (Pubitemid 47247294)
23. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000 25;162:225-33.
24. Dijk DJ. Slow-wave sleep deficiency and enhancement: implications for insomnia and its management. World J Biol Psychiatry 2010;11 Suppl 1:22-8.
25. Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci 2010;11:114-26.
26. Banks S, Van Dongen HP, Maislin G, et al. Neurobehavioral dynamics following chronic sleep restriction: dose-response effects of one night for recovery. Sleep 2010;33:1013-26.
27. Hornung OP, Regen F, Schredl M, et al. Manipulating REM sleep in older adults by selective REM sleep deprivation and physiological as well as pharmacological REM sleep augmentation methods. Exp Neurol 2006;197:486-94 (Pubitemid 43077157)
28. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21. (Pubitemid 40543126)
29. Bettica P, Squassante L, Groeger JA, et al. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology; in press.
30. Roth T, Lines C, Vandormael K, Ceesay P, et al. Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies. J Clin Sleep Med 2010;6:30-9.